ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fujimura, M
Right arrow Articles by Matsuda, T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujimura, M
Right arrow Articles by Matsuda, T
Eur Respir J 1995; 8: 1499-1505
Copyright © ERS Journals Ltd 1995


Clinical Trial

Prostanoids and cough response to capsaicin in asthma and chronic bronchitis

M Fujimura, Y Kamio, K Kasahara, T Bando, T Hashimoto, and T Matsuda

Cyclooxygenase products are released by chronic airway inflammation. Our working hypothesis for the present study was that prostanoids augment airway cough sensitivity. The effects of a cyclooxygenase inhibitor, indomethacin (100 mg.day-1 for 4 days), and a thromboxane synthesis inhibitor, OKY-046 (400 mg.day-1 for 4 days), on cough response to inhaled capsaicin were examined in eight patients with asthma, 10 patients with chronic bronchitis, and 10 normal subjects. Capsaicin cough threshold, the lowest concentration of capsaicin eliciting five or more coughs, was measured as an index of airway cough sensitivity. In asthmatics, the cough thresholds with indomethacin treatment (15.7 (GSEM 1.38) microM) and OKY-046 (10.2 (GSEM 1.20) microM) were significantly greater than the value with placebo (6.05 (GSEM 1.25) microM). In patients with chronic bronchitis, the cough threshold was significantly greater with indomethacin (5.94 (GSEM 1.50) microM) than with placebo (3.41 (GSEM 1.33) microM and OKY-046 2.97 (GSEM 1.43) microM). In normal subjects, the capsaicin cough threshold was not altered by indomethacin or OKY-046 treatment. These results support our hypothesis and suggest that thromboxane A2 may be one of the cyclooxygenase products augmenting airway cough sensitivity in asthma, but not in chronic bronchitis.


This article has been cited by other articles:


Home page
ChestHome page
P. V. Dicpinigaitis and R. V. Alva
Safety of Capsaicin Cough Challenge Testing
Chest, July 1, 2005; 128(1): 196 - 202.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
M G Belvisi and P Geppetti
Cough * 7: Current and future drugs for the treatment of chronic cough
Thorax, May 1, 2004; 59(5): 438 - 440.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
A. Xiang, Y. Uchida, A. Nomura, H. Iijima, T. Sakamoto, Y. Ishii, Y. Morishima, K. Masuyama, M. Zhang, K. Hirano, et al.
Involvement of thromboxane A2 in airway mucous cells in asthma-related cough
J Appl Physiol, February 1, 2002; 92(2): 763 - 770.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
M J Doherty, R Mister, M G Pearson, and P M A Calverley
Capsaicin responsiveness and cough in asthma and chronic obstructive pulmonary disease
Thorax, August 1, 2000; 55(8): 643 - 649.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the European Respiratory Society.